Eli Lilly and Company has developed an app for people living with Type II diabetes who use Trulicity, the company’s once-per-week injectable diabetes medication that also works with a click-activated ...
INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results